BioSpace News Archive

The results from a six patient case series indicate a reduction in the number of procedures required, the time taken to heal, and the overall economic cost of healing

Technavio’s global dental cleansing tablet market research report forecasts the market to grow at a CAGR of around 6% during the forecast period.

TOP 3 FAQS ANSWERED

Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed

WW commissions global research aligned with vision to become the world’s partner in wellness

Eli Lilly and Company announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira® (adalimumab) in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive.

European Approval Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in the Pivotal Phase 3 EORTC1325/KEYNOTE-054 Trial

Cipher Pharmaceuticals (TSX:CPH) today announced that its New Drug Submission (“NDS”) for plecanatide for irritable bowel syndrome with constipation (“IBS-C”) has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) (“Synergy”) in February 2018.

Cellect Biotechnology (Nasdaq: APOP), a developer of a novel stem cell production technology, announced that KORIL-RDF, has approved Cellect’s grant application, submitted with Cell2in, a Korean cell therapy company with whom a collaboration agreement was signed recently.

RenalSense® announced today that it is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of Professor John Kellum.